Transcode Therapeutics, Inc. cotiza a 1.68 USD y tiene una capitalización bursátil de $28M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clini…
| Métrica | RNAZ | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -335.4% | -40.4% | -295.0% |
| ROA | -21.3% | -32.0% | +10.7% |
| Current Ratio | 6.29 | 2.84 | +3.45 |
| Debt / Equity | — | 0.28 | — |